PPT-CDK4-6 INHIBITORS IN Breast Cancer: Optimal Treatment Sequencing

Mansoor A Khan BS MS BCOP OncologyHematologyBMT Clinical Pharmacist King Abdulaziz Medical City Jeddah Ministry of National Guard Health Affairs 1 Satellite Symposium 2 nd Saudi . Andrew Gentles. CCSB NGS workshop. September 2012. You’ve slogged through QC, trimming, alignment, realignment, variant calling. What next ?. Mutational processes molding the genomes of 21 breast cancers/The life history of 21 breast cancers. and Opportunities. This program will include a discussion . of off-label treatment and investigational agents not approved by the FDA for use . in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. CDK 4/6 Inhibitors in Breast Cancer Expert Perspectives on New Data Faculty Javier Cortes, MD, PhD Head Breast Cancer Program Oncology Department Ramon y Cajal University Hospital Madrid, Spain What’s Positive about Triple Negative Breast Cancer ? Julie R. Gralow, M.D. Jill Professor Endowed Professor of Breast Cancer Director, Breast Medical Oncology Seattle Cancer Care Alliance University of Washington School of Medicine Targeting endocrine-resistance pathways in breast cancer Clara Natoli, Chieti Endocrine responsive breast cancer Luminal A High expression of ER & ER-related genes Lower An Interactive Oncology Grand Rounds Series. Joyce O’Shaughnessy, MD. Chair, Breast Cancer Research Program. Baylor Charles A Sammons Cancer Center. Celebrating Women Chair in Breast Cancer Research. Julie R. Gralow, M.D.. Director, Breast Medical Oncology. Jill Bennett Endowed Professor of Breast Cancer. Professor, Global Health. University of Washington School of Medicine. Fred Hutchinson Cancer Research Center. Steven J. Katz MD MPH. Professor of Medicine and Health Management and Policy. University of Michigan . Allison Kurian MD M Sc.. Professor of Medicine and Medical Genetics . Stanford University . Guidelines 2019. in Advanced Solid Tumors. EDRN Biomarker Development Lab. Arul M. Chinnaiyan, M.D., Ph.D.. American Cancer Society Research Professor. Howard Hughes Medical Institute. Sequencing. Buccal swab . or. Blood. Medication Teaching The Center for Breast Cancer Mass General Cancer Center 2 Topics to Discuss • What are Aromatase Inhibitors? How do they work in the body? • Reasons for taking an Aromatase I tablet the next day.Aromatase inhibitors can interact with other medications specialist or doctor.Always tell any other doctor, dentist or pharmacist inhibitor.oestrogen in the body, it is possible to 1 of 15 and management of oestrogen deciency symptoms and arthralgia in women treated for breast cancer Key points 1. An early menopause, estrogen deciency symptoms and arthralgia are common s Mohammed A. Suwaid, MD. Board-certified Medical Oncologist. Anbar Cancer Center. AGENDA. Cancer . Oncology. Role of MDT in managing cancer. Surgical treatment. Radiation treatment. Systemic treatment.